Related references
Note: Only part of the references are listed.High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
Wolfgang Warsch et al.
BLOOD (2011)
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
Andrea Hoelbl et al.
EMBO MOLECULAR MEDICINE (2010)
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
F. Fei et al.
LEUKEMIA (2010)
Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells
Yan Cheng et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2009)
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
David T. Teachey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Sara Redaelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
L. S. Steelman et al.
LEUKEMIA (2008)
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
Oliver Ottmann et al.
BLOOD (2007)
Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo
Guang-Biao Zhou et al.
BLOOD (2007)
Oridonin inhibited the tyrosine kinase activity and induced apoptosis in human epidermoid carcinoma A431 cells
Dan Li et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2007)
Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells
Song Jin et al.
CANCER BIOLOGY & THERAPY (2007)
Oridonin-induced A431 cell apoptosis partially through blockage of the Ras/Raf/ERK signal pathway
Dan Li et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice
Yiguo Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity
Malcolm A. Meyn et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia
Steven M. Kornblau et al.
BLOOD (2006)
BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion
A. Jin et al.
ONCOGENE (2006)
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
A Burchert et al.
LEUKEMIA (2005)
Philadelphia positive acute lymphoblastic leukaemia of childhood
LK Jones et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger et al.
BLOOD (2005)
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
YG Hu et al.
NATURE GENETICS (2004)
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells
S Chu et al.
BLOOD (2004)
Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation
CL Zhang et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2004)
The biology and therapy of adult acute lymphoblastic leukemia
S Faderl et al.
CANCER (2003)
Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics
R Kurzrock et al.
ANNALS OF INTERNAL MEDICINE (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells
A Klejman et al.
EMBO JOURNAL (2002)
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia -: results of the prospective multicenter LALA-94 trial
H Dombret et al.
BLOOD (2002)
NF-κB in cancer:: From innocent bystander to major culprit
M Karin et al.
NATURE REVIEWS CANCER (2002)
Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells
RR Hoover et al.
ONCOGENE (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Philadelphia chromosome-positive acute lymphocytic leukemia
JP Radich
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2001)
Share Paper
